← Back
Data updated: Jun 28, 2026
NOVATECH SA
Pharma Pharmaceuticals
NOVATECH SA is a pharmaceutical company with 1 FDA-approved products.
2017
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
NOVATECH SA's Key Drugs
NOVATECH SA's core commercial portfolio centers on STERITALC — its most strategically important drugs approved in the last 15 years.
NOVATECH SA's Recent FDA Approvals
New NDA/BLA approvals for NOVATECH SA over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
NOVATECH SA's Therapeutic Areas
Disease areas where NOVATECH SA has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
NOVATECH SA Pipeline Snapshot
Active clinical trials for NOVATECH SA across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • STERITALC leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2017-05-01
- Latest
- 2025-06-10
- Applications
- 1